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Active-site mutants of the VanC2 D-alanyl-D-serine ligase, 
characteristic of one vancomycin-resistant bacterial phenotype, 
revert towards wild-type D-alanyl-D-alanine ligases 
Vicki L Healy, Neon Park and Christopher T Walsh 
Background: The rising number of vancomycin-resistant enterococci (VRES) is 
a major concern to modern medicine because vancomycin is currently the ‘last 
resort’ drug for life-threatening infections. The D-alanyl-D-X ligases (where X is 
an hydroxy or amino acid) of bacteria catalyze a critical step in bacterial cell-wall 
peptidoglycan assembly. In bacteria that produce glycopeptide antibiotics and in 
opportunistic pathogens, including VREs, D-, D-ligases serve as switches that 
confer antibiotic resistance on the bacteria themselves. Peptidoglycans in 
vancomycin-sensitive bacteria end in D-alanyl-D-alanine, whereas in vancomycin- 
resistant bacteria they end in D-alanyl-D-lactate or D-alanyl-D-serine. 
Results: We demonstrate that the selective utilization of D-serine by the 
Enterococcus cssseliflavus VanCP ligase can be altered by mutagenesis of one 
of two residues identified by homology to the X-ray structure of the Escherichia 
co/i D-alanyl-D-alanine ligase (DdlB). The Arg322+Met (R322M) and 
Phe%BO+Tyr (F25OY) ligase mutants show a 36-44-fold decrease in the use of 
D-serine, as well as broadened specificity for utilization of other D-adI acids in 
place of D-serine. The F25OY R322M double mutant is effectively disabled as a 
D-alanyl-D-serine ligase and retains 10% of the catalytic activity of wild-type 
D-alanyl-D-alanine ligases, reflecting a 6,000-fold switch to the D-alanyl-D-alanine 
peptide. Correspondingly, the Leu282+Arg mutant of the wild-type E. co/i DdlB 
produced a 560-fold switch towards D-alanyl-D-serine formation. 
Conclusions: Single-residue changes in the active-site regions of D-, D-ligases 
can cause substantial changes in recognition and activation of hydroxy or amino 
acids that have consequences for glycopeptide antibiotic efficacy. The 
observations reported here should provide an approach for combatting 
antibiotic-resistant bacteria. 
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Introduction 
Vancomycin resistance in the gram-positive pathogenic bac- 
teria is of, particular concern among health professionals. 
Vancomycin-resistant enterococci (VRE) have increased 
over ZO-fold in prevalence since their discovery a decade 
ago [l], a phenomenon approaching epidemic proportions 
that could convert the glycopeptide antibiotic vancomycin 
from its current niche as the ‘last resort’ antibiotic for life- 
threatening infections into a very limited single-use thera- 
peutic agent. Clinical phenotypes for VRE isolates have 
been designated VanA, VanB, or VanC [2,3] based on 
three criteria: inducibile versus constitutive resistance, 
susceptibility to vancomycin versus the related molecule 
teicoplanin, and the minimal inhibitory concentration 
(MIC) in VRE. Thus the most common clinical pheno- 
type, VanA, is inducible by vancomycin and teicoplanin, 
has an MIC about three log higher (1 l&/ml to 1000 &ml) 
for antibiotic than that of susceptible bacteria [4], and is 
rapidly spread through bacterial populations. VanB is very 
similar to the VanA phenotype except that it is not 
inducible by teicoplanin [4]. The VanC phenotype has 
been detected in fewer clinical isolates [5,6]; recent isolates 
have included the clinically significant human pathogens 
Enterococcus faecalis and Enterococcus faecium, however [7]. 
The VanC phenotype is largely constitutive [8,9], suscep- 
tible to teicoplanin, and shows about a one log elevation 
in MIC [lo]. 
At one level of molecular analysis, VanA and the related 
VanB phenotype differ from VanC in that the expression 
of five genes (VanR, Vans, VanH, VanA, and VanX) is nec- 
essary and sufficient for antibiotic resistance in the first 
two phenotypes [ll-131, whereas the VanC phenotype 
does not require VanR, Vans, and VanH and expresses the 
VanC ligase (which is involved in cell-wall peptidoglycan 
assembly) in place of the VanA (or VanB) ligase. At 
another level, however, the three clinical phenotypes of 
vancomycin resistance stem from a fundamentally similar 
switch in the specificity of a key enzyme in peptidoglycan 
assembly-a D-alanyl-D-alanine (D-Ala-D-Ala) ligase is 
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Illustration of vancomycin interacting with the peptidoglycan termini of (lactate-specific residues shown in green); (c) mildly vancomycin- 
(a) vancomycin-sensitive bacteria, N-acyl-D-Ala-o-Ala; (b) vancomycin- resistant bacteria of the VanC group, f+acyl-D-Ala-D-Ser (with serine- 
resistant bacteria of the VanA, VanB or Leucortostoc mesenteroides type specific residues shown in green) interacting with vancomycin. 
replaced or competed by a D-Ala-D-X ligase (encoded by 
VanA, VanB, or VanC genes). Bacteria that have peptido- 
glycan termini with the D-Ala-D-Ala motif bind van- 
comycin with high affinity, resulting in the blockage of 
enzymatic cross-bridge formation between adjacent 
peptide strands at the penultimate D-Ala residue, which 
leads to a concomitant decrease in wall tensile strength, 
which in turn leads to osmotic lysis of the bacterium. 
Peptidoglycan termini ending in D-alanyl-D-lactate (D-Ala- 
D-Lac) or D-alanyl-D-serine (D-Ala-D-Ser) have lOOO-fold 
[14] or sixfold [15] lower affinity, respectively, for van- 
comycin, mirroring the MIC values observed, and quanti- 
tatively accounting for resistance. The altered D-Ala-D-X 
peptidoglycan termini arise through the action of VanA, 
VanB, or VanC D-Ala-D-X ligases acting instead of, or in 
competition with, the normal D-Ala-D-Ala ligase in the 
bacterial cytoplasm. 
In this sense, vancomycin resistance is a molecular disor- 
der of D-Ala-D-X ligases where X is Ala in sensitive 
strains and Lac or Ser in resistant gram-positive bacteria. 
To understand the switch in specificity and to permit 
rational design of D-, D-ligase inhibitors, with the intent 
of reversing vancomycin resistance, we have been carry- 
ing out structure-function studies on the D-, D-ligase 
(Ddl) family, including the Escherichia coli DdlA and 
DdlB isoforms [16,17], the VanA D-Ala-D-Lac ligase 
[14,18], E. co/i Ddl mutants with a VanA-type gain-of- 
function [ 191, the depsipeptide-forming ligase from Leu- 
conostoc mesenteroides (Lm) [ZO] and, most recently, the 
VanC-type D-Ala-D-Ser ligase [Zl]. The VanA and VanB 
phenotypes differ from the VanC phenotype in that in 
the first two, a D-, D-depsipeptide is made, in which the 
amide NH to oxoester switch is the molecular determi- 
nant of the elevated K, for the antibiotic, whereas the 
VanC-type continues to make a D-, D-dipeptide product 
in which the methyl sidechain of the carboxy-terminal 
D-Ala is replaced by the larger, polar CH,OH substituent 
of D-Ser that is the source of molecular dislocation when 
complexed with vancomycin (Figure 1). 
In previous studies we have utilized the crystal structure 
of E. coli DdlB [Z] to guide mutagenesis studies that led 
to some understanding of the switch from dipeptide 
D-Ala-D-Ala to depsipeptide D-Ala-D-Lac synthesis. The 
E. co/j DdlB Tyd16+Phe (Y216F) mutant gains 
D-Ala-D-Lac activity [ 191 whereas a corresponding 
phenylalanine to tyrosine mutation in the D-, D-ligase 
from the vancomycin-resistant L. mesenteroides loses dep- 
sipeptide ligase activity but retains D-, D-dipeptide ligase 
function [ZO]. In this study, we have begun to address 
specificity determinants between the Ddl and VanC pro- 
teins that specify D-Ser versus a second D-Ala (D-Ala,) in 
a D-, D-dipeptide product. Whereas the wild-type VanC2 
ligase from Enterococcus cassel$av.us has a 240-fold prefer- 
ence for using D-Ser over D-Ala, (400-fold reported by 
Park et al. [Zl]), mutation of two VanCZ residues, Phe250 
and Arg322, which are predicted to interact with D-X, 
leads to a D-Ala-D-X ligase that now activates D-threo- 
nine, D-allothreonine, and D-homoserine at least lo-fold 
more efficiently than does the wild-type VanC2 ligase. 
The double mutant PheZSO+Tyr, ArgSZZ+Met (FZSOY 
R322M) VanC2 ligase has been reverted almost exclu- 
sively back to a D-Ala-D-Ala ligase. Analogously, muta- 
tion of Leu282 in E. co/i DdlB (which corresponds to 
residue 322 in VanC) leads to discrimination in favor of 
D-Ser over D-Ala,. 
Research Paper Analysis of the bacterial vancomycin-resistance phenotype Healy, Park and Walsh 199 
Figure 2 
(a) 
Vanc2 El4 VI7 SPI Hi03 El08 G188 s187 b50 11255 b56 b95 N312 M314 p315 G316 F317 T318 H320 2321 B322 Y323 
DdlB El5V18 s22ti63 E68 Gi49 &SO &lo !%215 k’16 &!55 N272 s274 p275 !&76 M277T278 H280 &81 b82 v283 
DdlA !i V S !i E GSVKVRNL P G F T I s M Y 
LmDdl E V S !=I E G S V K E R N L PGFTMSCF 
W 63 
Chemistry&Biology 
Choice of mutations predicted to affect D-Ala-D-X recognition in the subscripts refer to the postions of the amino acids in the primary 
VanC2 ligase by comparison to D-Ala-D-Ala ligases. (a) Alignment of sequence of the corresponding enzymes. (b) E. co/i DdlB residues 
residues (using singleletter amino-acid code] in D-, D-figases from within 4 A of any atom of the phosphinate transition-state analog, which 
E. co/i (DdlA and DdlB), Leuconostoc mesenteroides (Lm Ddl) and defines the active site. (c) A comparison of the distance between the 
Enterococcus casseliflavus (VanCP) based on X-ray analysis of E. co/i 
DdlB [22] that lie within a 6 A sphere of any atom of the phosphinate 
sidechain methyl of the bound phosphinate in f. co/i DdlB to Tyr210 
transition-state analog. Those residues within 4 A are underlined. The 
and Leu282 sidechains and a model for VanCP with putative distances 
to Phe250 and Arg322M, assuming equivalent orientations. 
ReSUltS 
Rationale for F25OY and R322M mutations 
Based on sequence homology (Figure Za), the amino acids 
shown by X-ray analysis to be within 4 A of the phosphi- 
nate transition-state inhibitor crystallized with E. co/i DdlB 
[ZZ] are identical to those of VanC2 except for Tyr210 and 
Leu282, whose locations are noted in Figure02b. The 
Tyr210 and Leu282 sidechains are 3.7 and 4.7 A, respec- 
tively, from the methyl group in the transition-state analog 
that corresponds to the methyl sidechain in D-Ala, 
(Figure 2~). A model for VanCZ with equivalent orientation 
would place PheZ50 and Arg322 in van der Waals contact 
with the CH,OH sidechain of a D-Ser variant of a phosphi- 
nate transition-state analog. Thus the corresponding 
VanC2 residues, PheZ50 and Arg322, might be responsible 
for the Z40-fold preferred K, of the VanC2 ligase for serine 
compared to alanine in the second site. To test this 
hypothesis, we constructed the F250Y and R3ZZM VanC2 
single mutants, as well as the double mutant. The R322M 
mutation was made instead of the Arg322+Leu (R322L) 
mutation because the arginine to methionine mutation 
yields a less bulky sidechain, and E. coli DdlA has methio- 
nine in this position (Figure Za). We expected these muta- 
tions to selectively disable D-Ala-D-Ser ligase activity and 
augment D-Ala-D-Ala ligase activity. The single mutants 
were purified in a manner analogous to wild-type VanC2, 
to > 95% homogeniety, as assayed by SDS-PAGE (data 
not shown). The FZSOY R322M double mutant was, 
however, substantially more problematic to obtain in quan- 
tity, as it is much less soluble than either single mutant or 
the wild-type VanC2 ligase. 
R322M and F25OY VanC2 D-Ala-D-X ligases 
Initial analysis of the regioselectivity of the wild-type 
VanC2 ligase for substrates in the carboxy-terminal posi- 
tion demonstrated recognition of only two D-amino acids 
at appreciable rates: D-Ser (k,,t/K, = 7.0 x 1O-3 M-‘s-1) 
and D-Asn (2.3 x 1O-3 M-*s-l). In contrast, recognition of 
D-Thr was very low (9.3 x 1O-5 M-‘s-1) as was D-Ala 
(2.9 x 10-5 M-is-i); values of4.5 x 10-3, 1.2 x 10-3, 2.8 x lO-!j, 
and 1.1 x 1O-5 M-‘s-l, respectively were reported by Park 
et al. [Zl]. Because VanCZ is believed to have little 
uncoupled ATPase activity, each of the two single- 
mutant VanC2 ligases was assayed for recognition of 
various D-amino acids, using a spectrophotometric assay 
in which the production of ADP is coupled to the oxida- 
tion of NADH through pyruvate kinase (PK) and lactate 
dehydrogenase (LDH). From these assays, it became 
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Figure 3 
The ability to activate o-amino acids (D-X) in o-Ala-o-X ligase assays 
using (a) wild-type VanCP ligase compared to (b) the R322M and 
(c) the F25OY single mutants. Catalytic efficiency assays measuring 
k,,,/K,(o-X) for the F25OY and R322M single mutant VanC2 ligases 
were measured using 18 ug or 17 pg enzyme, 10 mM D-Ala, and 
21 mM D-iSOTvX3 or 42 mM DL-iSOnK?rS of the indicated amino acids, 
as described in the Materials and methods section. For wild-type 
VanC2, 34 ug enzyme, 10 mM o-Ala, and 10 mM D-SrtkO acids or 
20mM oL.-amino acids were used, as previously reported [21]. 
A-T, allothreonine; H-S, homoserine; Am-B, a-amino-n-butyric 
acid; Lac, lactate. 
clear that, rather than just a specific reversal of selectiv- 
ity from a D-Ala-D-Ser back towards a D-Ala-D-Ala 
ligase, the ligase’s recognition selectivity was ‘loosened’. 
From Figure 3b and 3c it is evident that both single 
mutants demonstrate a substantial gain in ability to acti- 
vate and incorporate several D-amino acids, including 
D-Thr, D-Allothr, D-Leu, D-Lie, D-Phe, and D-Trp at mM 
levels. The nonproteinogenic D-Homoser is also recog- 
nized by the modified ligases. There is no detectable 
depsipeptide ligase activity with D-Lac, as is the case for 
wild-type VanC2. 
Steady-state kinetic data were acquired using the FZSOY 
and R322M single-mutant enzymes and compared to wild- 
type VanC2 for D-Se& D-Ala, D-Thr, D-Allothr, D-Homoser, 
D-Asn and D-Leu (shown in Table 1). Confirmation that 
the D-X and ATP-dependent coupled ADP-production 
assay was indeed measuring D-Ala-D-X dipeptide forma- 
tion was validated by thin-layer chromatography (TLC) 
analysis with 14C-D-Ala or 14C-D-Ser and comparison with 
Rr values of authentic L-, L-dipeptides for D-Ala-D-Ala, 
D-Ala-D-Asn, D-Ala-D-ser, and D-Ala-D-Thr activities 
(data not shown). 
Two trends are apparent from the kinetic data. First, both 
the R322M and F250Y mutants showed decreased cat- 
alytic efficiency as D-Ala-D-Ser ligases by about 10-12- 
fold (K,,,/K, = 7.0 x 1O-3 to 5.7 x lo-4 or 6.7 x lo--“ M-1s-1) 
compared to VanC2. Most of the effect, ninefold and sev- 
enfold, respectively, was a change to the K, for D-Ser, not 
a decrease of the k,,, for dipeptide bond formation. 
Second, there was a modest improvement in catalytic effi- 
ciency of each mutant as a D-Ala-D-Ala ligase, of threefold 
to fourfold. Although not necessarily interpretable alone, 
the change in catalytic efficiency ratios k,,JK,(D-Ala&: 
k,,JK,(D-Ser) was 36-fold for the R32ZM mutant and 
44-fold for the F250Y mutant (Table 2). 
The ability to process D-Thr was 12-fold higher in the 
F250Y mutant and 13-fold higher in the R332M mutant 
than in wild-type VanC2, using k,,JK, criterion, split 
between a twofold k,,, increase and about a fivefold 
improvement in K,. The recognition of D-Allothr and 
D-Leu is improved in the two single mutants by about five- 
fold, and recognition of D-Homoser some 17-23-fold, pre- 
dominantly as a result of lowering the K,. Not only are the 
p- and y-hydroxy D-amino acids more efficiently recognized 
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Table 1 Table 2 
Relaxation of specificity for D-X recognition by VanC2 VanC2 mutants with reversed specificity for D-Ala-o-Ala 
mutant ligases. ligase activity. 
Kinetic Wild-type R322M F25OY 
Substrate parameters VanCP VanCP VanCP 
k&(,,2 (D-Ala) Switch in 
Enzyme lQ$,,2 b--W specificity 
Wild-type VanC2 0.0042 1 -fold 
His-tagged wild-type VanCP 0.0017 0.40-fold 
F25OY VanC2 0.19 44.fold 
R322M VanCP 0.15 36-fold 
His-tagged F25OY R322M VanCP 26 6,200-fold 
p-Ser K, Ala, 
K, Ser, 
kat 
Ll’Knl 
K, ATP 
o-Ala K m2 
kk2 
o-Thr 
o-Allothr K,, 
kal 
LJKmz 
o-Homoser K,, 
4x1 
kalKl2 
o-Leu K m2 
k cat 
katJk2 
1.6 1.7 
2.6 23 
1092 780 
700 57 
0.42 0.25 
:, 100’ >100* 
>178+ z 760+ 
2.9 8.7 
>100* 16.8 
> 480b 1210 
9.3 120 
>42’ P-40’ 
>124+ > 569+ 
4.5 24 
241 37 
290 770 
2.0 35 
11.5 10.4 
1620 950 
230 150 
>48’ >84* 
> 29+ > 247+ 
1.0 5.0 
1.4 
17 
679 
67 
0.30 
>100* 
>1130+ 
12 
18.7 
1280 
1 20 
>45* 
>629+ 
27 
25 
690 
47 
14.6 
1360 
160 
> 84* 
>211+ 
4.5 
*highest concentration tested; +activity at highest concentration tested: 
K,,, in units of mM, hat in units of min-1, k,JK,,,2 in units of 1 Om5 M-IS-~. 
For assays that were performed in duplicate, the measured values of 
b, and K,from each independent experiment were within 20% of 
each other; the values of kJK<, were within 5% of each other. Assays 
were conducted using 15-20 ug enzyme in 1 ml reaction mixtures as 
described in the Materials and methods section. 
as nucleophilic substrates by the mutants, but the 
hydrophobic D-amino acids, D-Let+ D-Ile, D-Phe, and even 
D-Trp can be accommodated in the second amino-acid 
subsite of these two VanCZ mutant ligases. 
Although activation of most of the D-X amino acids is 
clearly dependent on D-Ala, we wanted to determine 
whether the VanC2 ligase could also utilize D-Ser in place 
of D-Ala at subsite 1. This activity can be assayed by D-ser- 
dependent ADP production in the ADP-coupled assay 
(ADP production became substantial at high concentrations 
of D-Ser). As shown in Figure 4, the ADP production even- 
tually begins to saturate around 100 mM for wild-type 
VanCZ, but not for F250Y or R322M VanC2. The greater 
D-Ser-D-Ser activity of wild-type VanCZ is consistent with 
the greater D-Ala-D-Ser activity measured for wild-type 
VanCZ compared to the other mutants. Confirmation that a 
D-Ser-D-Ser dipeptide was formed came from TLC of 
assays containing 14C-D-Ser in the absence of any D-Ala 
(data not shown). Even D-Homoser was able to support a 
low level of ATPase activity in wild-type and mutant 
VanC2 ligases (data not shown). 
The F25OY R322M double mutant of VanC2 ligase 
The double mutant FZSOY R322M of VanC2 ligase was 
constructed, expressed, and purified to see whether the two 
mutations had any synergistic effects on the specificity 
switch from a D-Ala-D-Ser ligase to a D-Ala-D-Ala ligase. 
Under a variety of induction conditions, the double mutant 
enzyme was greater than 90% insoluble. Because a histidine 
(His)-tag does not affect the activity of wild-type VanC2, 
we attempted to purify a small amount of soluble His- 
tagged protein; but the protein could not be purified to 
homogeniety and no significant amino-acid-dependent 
ATPase activity could be detected above the amino-acid- 
independent background ATPase activity, which was pre- 
sumably due to contaminating proteins. Thus, the insoluble 
His-tagged protein was solubilized with urea and the 
protein refolded on a nickel column using a decreasing urea 
gradient, providing soluble, active FZSOY R322M ligase for 
assays. As a D-Ala-D-Ala ligase, the double-mutant enzyme 
has a kcar/K<me of 2.57 x lOA M-‘s-1, a level readily measur- 
able over the amino-acid-independent ATPase back- 
ground (0.52 min-1 background compared to 15.5 min-1 
activity in the presence of 100 mM D-Ala), and about sev- 
enfold lower than unmodified His-tagged VanC2 
(1.70 x 10-s M-W; Figure 5). In contrast, FZSOY R32ZM 
has been essentially fully disabled as a D-Ala-D-Ser ligase. 
A ~ca&nZ of 1 x 1O-7 M-is-l was measured (Figure 5) 
barely above background activity, and 26-fold below the 
level of D-Ala-D-Ala ligase activity. The drop from 
9.77 x 10” to 1 x lo-’ M-‘s-l corresponds to a lOO,OOO-fold 
loss in catalytic efficiency for D-Ala-D-Ser formation. 
Because the presence of D-Ser did not inhibit enzyme activ- 
ity at 50 or 100 mM D-Ala, as would be expected for a low 
k,,, substrate, it is likely that the decrease in catalytic effi- 
ciency is primarily a K, effect. Both D-Ala-D-Ala and 
D-Ala-D-Ser activities were confirmed by TLC (data not 
shown). Although it is not yet clear if the renatured 
double mutant has properly folded to its fully native con- 
formation and full activity, nonetheless the specificity 
switch for D-Ala-D-Ser to D-Ala-D-Ala is reversed by 
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D-Ser-D-Ser ligase activity of wild-type and mutant VanC2 ligases. The 
dependence of ADP formation by wild-type VanC2, F25OY VanC2, 
and R322M VanC2 on o-Ser concentration in the absence of any o-Ala 
is shown. The assay conditions are as described in the Materials and 
methods section using 15-20 ug enzyme. 
. .~-.- -
Concentration of D-Ala or o-Ser (mM) 
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D-Ala-D-Ala and D-Ala-D-Ser ligase activities in the double-mutant 
F25OY R322M VanCP ligase. D-Ala-D-Ala synthesis and D-Ala-D-Ser 
synthesis were assayed at different o-Ala or D-Ser concentrations in 
the standard coupled spectrophotometric assay as described in the 
Materials and methods section. 
about 6,000-fold compared to untagged wild-type VanC2 
and 15,000-fold compared to His-tagged but otherwise 
wild-type VanC2 (Table 2). 
The Tyr256+Phe mutant of VanC2 ligase 
Tyr256 in VanC2 corresponds to Tyr216 in E. co& D-Ala- 
D-Ala ligase (Figure Za,b), a residue identified in the crystal 
structure as part of a hydrogen-bonded triad (with Serl.50 
and Gln1.5) that stabilizes the mobile Q loop (residues 
205-227) and sets up the catalytic active site geometry 
(Lys215 required for y-PO, transfer) in the enzyme-sub- 
strate complex [22]. A survey of D-, D-ligases shows either 
tyrosine or phenylalanine at this position in all D-Ala-D-X 
ligases except the depsipeptide-forming VanA and VanB 
ligases, which appear to have a different Q loop structure 
(Figure Za). When tyrosine is present (E. coli DdlA and 
DdlB; see Figure Za), dipeptide ligase activity and van- 
comycin sensitivity are observed [19,20]. When phenylala- 
nine is present (for example, Lm Ddl, Figure Za), there is 
phenotypic vancomycin resistance and gain of depsipeptide 
ligase activity. In particular, the Tyr216+Phe (Y216F) 
mutant of E. coli DdlB gains depsipeptide ligase activity 
[19] whereas the Phe216+Tyr (F216Y) mutant of Leuconqs- 
tot mesenteroides (a naturally vancomycin-resistant organism) 
retains D-&a-D-Ala ligase activity but loses D-Ala-D-Lac 
synthetic ability [ZO]. 
We examined a possible comparable role for Tyr2.56 by 
constructing the Tyr256+Phe (Y256F) VanC2 mutant as 
described in the Materials and methods section. When we 
overproduced the E. casselifiavus Y256F VanCZ, it was 
expressed at low levels in E. coli but could be purified 
and analyzed. The Y256F mutant protein is substantially 
disabled as a D-Ala-D-Ser ligase. Although the binding 
site for the first D-Ala (D-Ala,) appears to be intact 
(K,, = 0.6 mM), and D-Ala-D-Ser activity is still measur- 
able, no saturation was seen up to 100 mM D-Ser (uO at 
20 min-’ at this concentration of D-Ser) so the K, for 
D-Ser (2.6 mM in wild-type VanC2) may have been 
increased by at least two orders of magnitude. Likewise, 
Y256F VanC2 showed no tendency to saturate with D-Ala 
(K, D-Ala, > 180 mM) or D-Thr (K, D-Thr > 150 mM), 
suggesting a broadly incapacitated catalyst. 
Finally, the question of whether the mutant had gained 
detectable depsipeptide ligase activity was assayed using 
D-lactate, DL-hydroxybutyrate, and D-glycerate as D-X sub- 
strates. Under conditions that resulted in significant D-Ala- 
D-lactate and D-Ala-D-hydroxybutyrate production by 
VanA, corresponding production by Y256F VanC2 was not 
detected (data not shown). Even at pH 6.0, which results in 
almost 100% depsipeptide activity by VanA [19], D-Ala- 
D-glyceric acid was not detected in reactions incubated 
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Figure 6 
Phylogenetic tree of the D-, D-k&we family. 
The alignment was obtained using the 
program ClustalX(1.5) [32], as described in 
the Materials and methods section. Aori, 
Amycolatopsis orientalis; Baci, Bacillus 
subtilis; Ecas, Enterococcus casseliflavus; 
Efam, E. faecium; Efas, E. faecalis; Efla, 
E. flavesceus; Egal, E. gallinarium; Hinf, 
Haemophilus influenza; Leon, Lactobacillus 
confusus; Llei, Lactobacillus leichmannii; Lm, 
Leuconostoc mesenteroides; Lpla, 
Lactobacillus plantarum; Lsal, Lactobacillus 
salivarius; Stoy, Streptomyces toyocaensis; 
Styp, Salmonella typhimurium. 
WIA group 
\ / Leuwnostoc group 
Ala-Lx 
0.1 Chemistry & Biology 
VanANanB group 
Ala-Lac 
WIB group 
Ala-Ala 
with VanA or Y256F VanC2; D-Ala-D-Ala and D-Ala-D-% 
activities were confirmed by TLC, however (data not 
shown). Thus, this tyrosine to phenylalanine mutation is 
not sufficient for VanC2 to gain depsipeptide ligase activity. 
The Leu262+Arg mutant of E. coli DdlB 
We made a comparable mutant in E. coli DdlB, namely 
Leu282+Arg (L282R), in which the arginine sidechain 
corresponding to Arg322 in VanC2 (Figure 2c) was engi- 
neered into E. co/i D-Ala-D-Ala ligase. We had previously 
noted [23] a decline in catalytic efficiency of E. co/z’ L282R 
DldB as a D-Ala-D-Ala ligase. Repetition of these experi- 
ments confirmed the 18-fold increase in K, for D-Ala, 
(1.13 mM to 20.9 mM) in L282R and an 11-fold decrease 
in k,,, (1870 mini to 158 min-l) for a net drop in k,,JK, of 
2.76 x lo-2M-‘s-‘/1.27 x 104M-1s-1 of ZlO-fold. 
In contrast, when assayed as a D-Ala-D-Ser ligase the 
E. cor’i enzyme shows an improvement in D-Ser K, of 24- 
fold (56 to 2.4 mM) resulting in a D-Ser K,, similar to that 
of wild-type VanC2 (2.6 mM). There was a ninefold drop 
in k,,, (157 to 17.2 min-l), however, for a net gain of only 
threefold in catalytic efficiency as a D-Ala-D-Ser ligase 
(this activity was confirmed by TLC using i4C-Ser). 
Examining the ratio of [k,,dK,(D-AlaZ)]:[k,,,/K,(D-Ser)], 
there is about a .560-fold switch towards selective 
D-Ala-D-Ser ligase activity, driven mostly by the ZlO-fold 
decline in D-Ala-D-Ala ligase catalytic efficiency. In con- 
trast to the results for D-Ser, the catalytic efficiency for 
D-aminobutyric acid, which lacks a hydroxy group, 
decreased 30-fold from 1.78 x 10” M-Y to 5.88 x 
10-5M-1s-1 for DdlB L282R, suggesting a switch to 
preferential recognition of the CH,OH sidechain of D-Ser. 
Discussion 
Analysis of the specificity of D-, D-dipeptide formation by 
the D-, D-ligases involved in providing the dipeptidyl unit 
at the termini of peptidoglycan intermediates in bacterial 
cell wall biosynthesis has taken on some immediacy with 
the recent realization that vancomycin resistance, both in 
opportunistic clinical pathogenic gram-positive bacteria 
(VRE) and in the natural antibiotic immunity in the pro- 
ducer organisms (streptomycetes) [24], is due to altered 
ligase specificity. The family of D-Ala-D-X ligases can be 
subdivided into eight subgroups (Figure 6), five of which 
are D-Ala-D-Ala ligases physiologically, two D-Ala-D-Lac 
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ligases and the eighth, the VanC subgroup, has a 
D-Ala-D-Ser ligase. A change from D-Alaz to either D-Lac 
or D-Ser leads to a lowered affinity for vancomycin when 
the D-Ala-D-X moiety is displayed on peptidoglycan 
termini on the outer face of the cytoplasmic membrane of 
resistant enterococci [25,26], lactobacilli [27], or leuconosti 
[27]. The vancomycin resistance engendered by the 
switch from the peptidoglycan terminus D-Ala-D-Ala- 
COO- to D-Ala-D-Lac-CCC- is thought to be due in sub- 
stantial part to loss of a hydrogen bond between the 
dipeptide NH and one of the backbone carbonyls of van- 
comycin (Figure l), whereas the D-Ala-D-Ser-CCC- alter- 
ation preserves the hydrogen-bonding network between 
the dipeptide and the antibiotic, but the CH,OH 
sidechain of D-Ser is presumed to pack less well against 
the concave surface of the rigid cup-shaped vancomycin. 
A starting point for structure-function analysis of the 
switch in D-Ala-D-X ligase selectivity has been the X-ray 
structure of the E. coli DdlB D-Ala-D-Ala ligase complexed 
with a tightly binding phosphinate analog of a tetrahedral 
reaction intermediate [ZZ], which has allowed definition of 
the ligase active site and led to structure-driven mutagene- 
sis studies of E. co/i DdlB [23]. The VanC ligase 
(D-Ala-D-Ser) and E. co/i Ddl ligase subgroups haye a very 
strong conservation of residues found within a 4 A sphere 
of the E. co/i DdlB active site with the two changes noted 
in Figure Za,b. The TydlO and Leu282 residues in the 
E. co/i Ddl active-site structure are 3.7 and 4.3 A, respec- 
tively, from the methyl sidechain of the cocrystallized 
transition-state analog inhibitor (Figure 2~). Modeling a 
similar arrangement for the VanC2 ligase active site sug- 
gested the two distinct residues Phe250 and Arg322 would 
occupy comparable positions and, in particular, that the 
amidino sidechain could hydrogen bond to the CH,OH 
sidechain of a D-Ala-D-Ser tetrahedral intermediate (puta- 
tively at 2.8 and 2.7 A in the model of Figure 2~). This 
model formed the basis of the choice of F250Y and R322M 
mutants constructed in this work. 
We had anticipated that elimination of the guanidinio 
moiety in R322M would decrease any favorable interaction 
with the CH,OH sidechain of D-Ser in the second subsite 
of a D-Ala-D-X ligase. Indeed the observed result is a 
lO-12-fold drop in the k,,JK, ratio for D-Ala-D-Ser cat- 
alytic efficiency, and the D-Ala-D-Ala production rose 
three- to four-fold. But, more significantly, the replace- 
ment of the long cationic arginine sidechain of residue 322 
by the shorter linear methionine sidechain should create 
space for improved recognition of bulkier, larger D-X 
groups, and a significant broadening of specificity was 
observed, as noted in Figure 3. In particular, both the 
2R,3R and 2R,3S diastereomers of threonine (D-Thr, 
D-Ahothr) were activated with 12- and S-fold improvement 
in catalytic efficiency. Likewise, activation of D-Homoser, 
which is very poorly incorporated by wild-type VanC2 
ligase, is increased l&fold. The other single mutant, 
FZSOY, shows equivalent trends: a comparable lowering 
of activity as a D-Ala-D-Ser ligase, marginal gain as a 
D-Ala-D-Ala ligase, and a net promiscuity in D-X activa- 
tion. It is not obvious exactly how FZSOY substitution 
relaxes D-X specificity; this will require X-ray structures 
of VanC2 and/or these mutants. 
Even though each single mutant had a 36--14-fold alter- 
ation in favor of D-Ala-D-Ala formation over D-Ala-D-Ser, 
initial studies with the F250Y R322M VanCZ double 
mutant showed about a 6,000-fold switch, largely due to 
selective loss of D-Ala-D-Ser ligation. It is not yet clear 
whether the double mutant FZSOY R322M is properly 
folded and fully native; at worst it has become a much 
better D-Ala-D-Ala ligase than a D-Ala-D-Ser ligase with 
decreased catalytic efficiency. 
Neither VanC2 nor the F250Y or R322M mutants have 
detectable ability to activate D-Lac, confirming that the 
ability to turn D-hydroxy acids into effective nucleophiles 
is not a property of this ligase subgroup. Although we 
have noted an experimental correlation of D-Lac activa- 
tion with a Y216F mutant (DdlB numbering) in E. co/i 
Ddl and Lm Ddl [19,20], mutation of the corresponding 
tyrosine in VanC2 to phenylalanine (Y256F) did not 
produce detectable depsipeptides, either from D-Lac or 
the CH,OH containing cognate, D-glycerate. Thus, we do 
not understand yet how to get D-, D-depsipeptide ligase 
activity in a VanC ligase framework. 
The mutant in E. co/i DdlB that should go the ‘other way’, 
and turn a D-Ala-D-Ala ligase into a D-Ala-D-Ser ligase, is 
L282R. Indeed this E. coli DdlB mutant ligase is ZlO-fold 
disabled in catalytic efficiency for making D-Ala-D-Ala 
and about threefold improved for yielding D-Ala-D-Ser, 
for a net swing of about 560-fold for selecting D-Ser over 
D-Ala in the second position of the D-Ala-D-X dipeptide. 
It may be worth crystallizing and determining the struc- 
ture of this mutant, preferably with a CHzOH-containing 
phosphinate analog, to see whether the guanidino 
sidechain of the newly introduced arginine residue is 
indeed in contact with the CH,OH substituent. 
Significance 
The D-nhuryl-D-alanine ligases of both gram-negative 
and gram-positive bacteria occupy a crucial step in 
bacterial cell-wall peptidoglycan assembly, and are 
themselves antibacterial targets. In the gram-positive 
soil bacteria that produce glycopeptide antibiotics 1241 
and in opportunistic human pathogens (such as the 
vancomycin-resistant enterococci, VREs) 111-131, 
these D-, D-hgaaes also serve as switches that confer 
antibiotic resistance on the bacteria themselves. The 
cell-wall peptidoglycan termini of vancomycin-sensi- 
tive bacteria, for example, end in the motif 
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D-Ala-D-ma. In contrast, vancomycin-resistant pepti- 
doglycans end in D-Ala-D-hydroxy acid (in the case of 
the VanA and VanB phenotypes) or D-Ala-D-Ser in 
the VanC phenotype. These differences are due to a 
change in the D-, D-ligase. Understanding the molecu- 
lar basis of the D-X switching among members of the 
D-Ala-D-X ligase family should help in deciphering 
antibiotic resistance and immunity mechanisms and in 
the design of effective ligase inhibitors. Using the 
Edzerichia coli D-Ala-D-Ala ligase (Ddl) X-ray struc- 
ture as a guide, we have identified and mutated active- 
site residues in the VanC2 and Ddl ligases that alter 
D-X recognition in both D-, D-dipeptide and D-, D-dep- 
sipeptide formation (two peptidoglycan synthesis steps 
that involve the D-, D-bgases). Our findings confvm 
that certain D, D-ligase residues are critical for deter- 
mining D-X recognition, and might provide a way to 
combat bacterial antibiotic resistance in pathogens. 
Materials and methods 
Materials 
Culture media was obtained from Difco Laboratories. The expression 
vectors pET22b and pETl5b, and the competent E. co/i strains 
BL21 (DE3) and BL21 (DE3) pLysS were obtained from Novagen. The 
competent E. co/i strain DH5a was purchased from GibcoBRL. 
Oligonucleotides were obtained from Integrated DNA Technologies, Inc. 
Restriction endonucleases and T4 DNA ligase were obtained from New 
England Biolabs, Inc., and pfu DNA polymerase from Strategene. ATP, 
amino acids, L-Ala-L-X dipeptides, phospho(enol)pyruvate, chloram- 
phenicol, ampicillin, bovine serum albumin, dithiothreitol (DllJ, and 
buffers were purchased from Sigma. o-lactate was obtained from Fluka, 
and o-glyceric acid from Aldrich. Isopropyl-thio-5-o-galactoside and 
L-Ser-L-Ser were purchased from Bachem Biosciences. Reduced nicoti- 
namide adenine dinucleotide (NADH), lactate dehydrogenase (LDH), 
and pyruvate kinase (PK) were obtained from Boehringer Mannheim Bio- 
chemicals. Radiolabeled 14C-o-alanine, 14C-D-serine, “C-D-hCtate, and 
“c-DL-glyCet’iC acid (0.1 mCi/mL, 55 uCi/umol) were purchased from 
American Radiolabeled Chemicals Inc. Thin-layer chromatography (TLC) 
cellulose plates were obtained from Kodak, and TLC silica plates from 
Whatman. Plasmid pVANC2 expressing the E. casseliflavus ATCC 
25788 VanC2 gene has been described previously (211. 
Recombinant DNA methods 
Recombinant DNA techniques were performed as described elsewhere 
[28]. Preparation of plasmid DNA, gel purification of DNA fragments, and 
purification of polymerase chain reaction (PCR)-amplified DNA fragments 
were performed using a GlAprep spin plasmid miniprep kit, a QIAEX II 
gel extraction kit, and a QlAquick PCR purification kit, respectively 
(QIAGEN). 
Site-directed mutagenesis 
Site-directed mutants F25OY and R322M were constructed using the 
megaprimer method [291 with pVANC2 as the template (211. In the 
first round, a DNA fragment was amplified for the F25OY mutant using 
the primer Fl (5’-GTAGACGGClTfTACGATilTGAAG~3’-mismatch 
in bold) and primer wtl @‘-GCGGATCCCTCAlTTGACTTCCTCCT- 
T-TGCTAAGACAAGll-flTGG-3’). 
For the R322M mutant, the primer Rl (5’CGAGTCACTCCATGTATC 
CTGCC-3’) and primer wtl were used. The second run was achieved 
using the respective gel-purified PCR-amplified DNA fragment and 
primer wt2 (5’-GAAACATATG AAAAAAATCGCCAT-TAllTl-fGG-3’) 
with pVANC2 as template. For the Y256F mutant and the F25OY 
R322M double mutant, the splicing by overlap extension method (301 
was used with plasmids pVANC2 and pVANC2.F250Y as templates, 
respectively. In the first round, the upstream and downstream 
sequence of the mutations were amplified using the primer pairs wt3 
(5’~CGGTCTAGAGGAAGGAAGAAACATATGAAAAAAATCGCCAT- 
TA-3’) Nl (5’-GAAGAAAAGTTCCAGCTGATCAGCG-3’) and wtl N2 
(5’~CGCTGATCAGCTGGAACTTTTCTTC-3’) for the F25OY mutant. 
Primer pairs wt3/Rl and wtllR2 (5’-GGCAGGATACATGGAGT- 
GACTCG-3’) were used for the F25OY R322M double mutant. The 
second run was achieved by using an approximately equimolar ratio 
(total amount about 20 ng) of the two gel-purified PCR-amplified frag- 
ments to be joined as template and the primer pair wt3Avtl. The result- 
ing purified PCR products were digested with Xbal and BarnHI, 
gel-purified, and subcloned into Xbal- and BarnHI-digested pET22b. 
The sequences were confirmed by DNA sequencing by the Molecular 
Biology Core Facility of the Dana Farber Cancer Institute (Boston, MA). 
Construction of His-tagged fusions 
pVANC2 and pVANC2.F250YR322M were digested with Ndel and 
BarnHI, gel-purified, and subcloned into Ndel- and BarnHI-digested 
pETl5b, giving pHVANC2 and pHVANC2.F250YR322M, respec- 
tively. The plasmids were then transformed into E. co/i strain DH5o 
and subsequently into E. colistrain BL21 (DE3) pLysS for expression. 
Overexpression and purification of protein 
Overexpression and purification of wild-type VanCP, and the F25OY, 
R282M, and Y256F mutants were performed as previously described 
[20], giving respectively 40 mg, 14 mg, 19 mg, and 6 mg from 2 L cell 
cultures. The His-tagged VanCP fusion was overexpressed in the same 
way as the untagged protein except that 34 ug/mL chloramphenicol 
was added to the culture media. The harvested cells were resus- 
pended in 20 mL of buffer A (50 mM NaPO,, pH 8.0,5 mM MgCI,, and 
10% glycerol), disrupted by French press (18,000 psi/k?), and cen- 
trifuged for 30 min at 100,000 x g. The supernatant was applied to a 
Ni-NTA Superflow (Cliagen) column (8 ml) preequillibrated with buffer 
A at a flow rate of 1 mUmin. After washing with 40 mL of buffer A and 
80 mL of buffer A containing 7.5 mM imidazole, the protein was eluted 
using a linear gradient of O-O.25 M imidazole in buffer A containing 
300 mM NaCl at a flow rate of 2 mUmin. The buffer was changed to 
buffer B (50 mM HEPES, pH 7.2, 150 mM KCI, 5 mM MgCI,, 5 mM 
DTT, and 20% glycerol) using a Centriprep 10 concentrator (Amicon), 
yielding 40 mg protein from 1 L of cell culture. The F25OY R322M 
double mutant initially could not be overexpressed using the pET22b 
vector transformed into E. co/i BL21 (DE3) or BL21 (DE3)pLysS. Good 
overexpression was obtained using pET26b vector transformed into 
BL21 (DE3) or pET15b or pET28b transformed into BL21 (DE3) pLysS. 
A 1 L culture of His-tagged F25OY R322M double mutant was grown, 
harvested, lysed, and centrifuged as described above. Over 90% of the 
protein remained in the pellet as assayed by SDS-PAGE (data not 
shown). The insoluble protein found in the cell debris pellet was solubi- 
lized using 50 mL buffer C (0.1 M NaPO,, 0.01 M Tris, pH 8.0, and 8 M 
urea) and incubated for one hour. After centrifugation for 30 minutes at 
100,000 x g, the supernatant was loaded on a 8 mL Ni-NTA Superflow 
column preequilibrated with buffer C. The protein was refolded using a 
linear gradient of 6-O M urea in 20 mM Tris-Cl, pH 7.4, 5 mM MgCI,, 
20% glycerol, 500 mM NaCI, and 0.5 mM ATP over 120 mL at 
1 mUmin. The protein was eluted with 20 mM Tris-Cl, pH 7.4, 
5 mM MgCI,, 20% glycerol, and 250 mM imidazole. The protein 
sample was then dialyzed into buffer B and centrifuged for 30 minutes 
at 100,000 x g, yielding 6 mg of protein. Wild-type and L282R DdlB 
were overexpressed and purified as described previously (231 
Protein quan tita tion 
Protein concentrations were determined using the method of Bradford 
with bovine serum albumin as standard (311. 
Enzyme assay by coupled ADP release 
Steady state kinetic constants for the ATP and D-X substrates were 
determined using a spectrophotometric assay where the production of 
ADP is coupled to the oxidation of NADH through PK and LDH (201. 
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Reaction conditions of 100 mM HEPES, pH 7.5, 10 mM KCI, 
10 mM MgCI,, and 5 mM ATP were used throughout this study. Kinetic 
parameters were determined using the equations 1 and 2 (see below) 
previously described [19,20]. To measure D-Ala-D-Ala activities, the 
enzymes were incubated in the above buffer in the presence of increas- 
ing concentrations of D-Ala; no other amino acids were present. For 
wild-type and mutant VanCP ligases, D-Ala-D-X activities were deter- 
mined in the presence of 10 mM D-Ala and corrected for the back- 
ground D-Ala-D-Ala activity. Equation 2 was used because in the case 
of K,<<[S,], the last term of equation 1 becomes very small compared 
to the second term. Because the D-Ala-D-Ala activty of the F25OY 
R322M VanC2 mutant is high compared to the D-Ala-D-Ser activity, it 
is possible that the D-Ala-D-Ser activity could be underestimated by 
substracting a constant value for the background D-Ala-D-Ala activity 
which might decrease in the presence of high D-Ser concentrations. To 
test this possibility, the D-Ala-D-Ala activity, of the F25OY R322M 
VanC2 mutant was tested in the presence of 10 mM 14C-DAla and 
increasing D-Ser concentrations and analyzed by TLC as described 
below. The level of D-Ala-D-Ala activity was constant within the range 
of error of the experiment, however. For wild-type VanC2, the K,, for 
D-Ala was determined using 15 mM D-Ser; for F25OY and R322M 
VanC2,50 mM D-Ser was used. The K, for ATP was determined in the 
presence of 10 mM D-Ala and 60 mM D-Ser. 
For wild-type and L282R DdlB, D-Ala-D-X activities were measured 
using 0.5 mM D-Ala. Equation 1 was used with the reported K,.,,, values 
of 0.0012 and 0.49 mM, respectively [23]. 
1 1 K, 1 -1 -c-+-P+ - 
v vm, v,, tq v,,, [s,l[s,l 
(1) 
1 1 K, 1 -=-+-- 
v lcnax blsx [S21 
(2) 
Enzyme assay by TLC 
The assay mixture included 0.2 mM 14C-D-Ala, 14C-D-Ser, “C-D-LaC, or 
‘4C-DL-glyceric acid (0.1 mCi/ml, 55 uCi/pmol), 100 mM HEPES, 
pH 7.5, 10 mM KCI, 10 mM MgCI,, 5 mM ATP and additional unlabeled 
amino acids with enzyme at room temperature. D-Ata-D-Lac and D-Ala- 
o-glyceric acid activities were also tested at pH 6.5 and 6.0 using 
100 mM MES buffer. D-Ala-D-Ala, D-Ala-D-Asn, D-Ala-D-Thr activities 
were analyzed using 14C-DAla, 10 mM unlabeled D-Ala, and 20 mM of 
the second substrate incubated with enzyme for 4 h. The D-Ala-D-Ala 
and D-Ala-DAsn reaction mixtures were analyzed on TLC cellulose 
plates as described previously 114,181. D-Ala-D-Thr reactions mixtures 
were separated on TLC silica plates (thickness, 250 urn; pore size, 
6OA) using 25% 1 M ammonium acetate in P-propanol for develop- 
ment (solvent A). D-Ala-DSer dipeptide formation was confirmed using 
14CD-Ser as described previously [21]. D-Ser-D-Ser activity was mea- 
sured using 14C-D-Ser and 5 mM unlabeled D-Ser. Before applying the 
reaction mixtures to TLC silica plates and developing with solvent A, 
unlabeled D-Ser was added to a final concentration of 50 mM. 
Phylogenetic tree of o-pligase family 
The alignment was obtained by using the default settings of program 
ClustalX(1.5) [32]. The tree was made based on the alignment and 
evaluated by the bootstrap method using 100 replications produced by 
the same program. 
Modeling of the structure of VanCP 
The VanCP structure was modeled based on the known structure of 
DdlB 1221. Initially, an alignment of DdlB and VanC2 was performed 
using the ClustalX program 1321 and sent to the Swiss-Model protein 
modeling service according to the standard procedure provided (331. 
Because this service does not model ligands, the D-Ata-D-Ser analog of 
the phosphinophosphate was modeled by adding an oxygen atom to the 
D-Ala-D-Ala phosphinophosphate from the DdlB structure at the C3’ 
position and by changing the Cl’ atom to a nitrogen. Swiss-pdbviewer 
[34] was used to three-dimensionally align the conserved amino acid 
residues of DdlB and VanCP and to add the ligand model to the active 
site of VanCP based on the position of the equivalent atoms in the D- 
Ala-D-Ala phosphinophosphate. One set of rotamers of F250 and R322 
in VanCP that align with those of Y210 and L282 in DdlB are shown 
along with their distances in angstroms to the phosphinophosphate 
analog in Figure 1 b. Because no energy minimization calculations have 
been performed, this model serves only as a starting point for 
structure-function studies. 
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